IgA nephropathy

What is IgA nephropathy?

IgA nephropathy, also known as Berger disease, is a kidney condition where abnormal deposits of immunoglobulin A (IgA) antibodies build up in the glomeruli—the tiny filters within the kidneys. This accumulation causes inflammation and damage, leading to blood and protein in the urine and potentially progressive kidney disease. Despite being classified as a rare disease, IgA nephropathy is actually the most common form of primary glomerulonephritis worldwide, affecting people of all ages but typically diagnosed in young adults. The condition has a complex, multifactorial cause involving genetic susceptibility and environmental triggers.

Key statistics

Symptoms

Common symptoms: Blood in urine (hematuria), protein in urine (proteinuria), swelling (edema), high blood pressure, fatigue, reduced urine output.

The hallmark symptom of IgA nephropathy is synpharyngitic gross hematuria—visible blood in the urine that appears within 1-3 days after an upper respiratory infection or sore throat. This distinguishes it from other kidney conditions where blood in urine may appear weeks after infection. Many patients notice their urine becomes cola-colored, tea-colored, or pink during these episodes.

Early symptoms often include microscopic blood in urine detected during routine testing, mild protein in urine, and occasional episodes of visible blood in urine following respiratory infections. Progressive symptoms may include persistent proteinuria, swelling in the legs and face, elevated blood pressure, and decreased kidney function. In advanced cases, patients may experience symptoms of chronic kidney disease including fatigue, nausea, decreased appetite, and difficulty concentrating.

Submit Your Paper

Causes and risk factors

IgA nephropathy has a multifactorial cause involving both genetic predisposition and environmental factors. The condition occurs when abnormally structured IgA antibodies are produced, often lacking certain sugar molecules (galactose-deficient IgA1). These abnormal antibodies form immune complexes that deposit in the kidney’s filtering units, triggering inflammation and scarring.

Genetic factors play a significant role, with several gene variants identified that increase susceptibility, particularly those affecting complement regulation and IgA production. Family clustering occurs in 5-10% of cases. Environmental triggers include respiratory tract infections, gastrointestinal infections, and possibly dietary factors like gluten. Risk factors include Asian or Caucasian ethnicity (higher prevalence), male gender, family history, and recurrent mucosal infections.

Prevention

Currently, there is no proven method to prevent IgA nephropathy since it involves complex genetic susceptibility factors that cannot be modified. However, early detection through screening can significantly impact outcomes. Regular urine testing, particularly for individuals with family history or recurrent respiratory infections with subsequent blood in urine, may lead to earlier diagnosis.

For families with multiple affected members, genetic counseling may be beneficial to understand inheritance patterns and risks, though no specific genetic test is currently used for predictive screening. Maintaining good general health, treating infections promptly, and avoiding nephrotoxic medications may help reduce disease progression once diagnosed.

Complications

Without proper management, IgA nephropathy can lead to serious complications. The most significant long-term consequence is chronic kidney disease (CKD) with potential progression to end-stage renal disease requiring dialysis or kidney transplantation. Approximately 20-40% of patients progress to kidney failure within 20 years of diagnosis.

Cardiovascular complications are common due to chronic inflammation, high blood pressure, and kidney dysfunction. These include increased risk of heart disease, stroke, and heart failure. Acute complications may include severe episodes of kidney inflammation (acute glomerulonephritis), rapid loss of kidney function, and nephrotic syndrome with significant protein loss, swelling, and increased infection risk.

Diagnosis

Diagnosis of IgA nephropathy requires a combination of clinical presentation, laboratory tests, and ultimately kidney biopsy confirmation. Initial testing includes urinalysis showing blood and protein, complete blood count, comprehensive metabolic panel including creatinine and estimated glomerular filtration rate (eGFR), and measurement of 24-hour urine protein or protein-to-creatinine ratio.

Specialized blood tests may include complement levels (C3, C4), antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), and hepatitis B and C screening to rule out other causes of glomerulonephritis. Kidney biopsy remains the gold standard for diagnosis, showing characteristic IgA deposits in the mesangium on immunofluorescence microscopy, along with varying degrees of inflammation and scarring on light microscopy.

The diagnostic journey often begins with routine urine testing or episodes of visible blood in urine following respiratory infections, leading patients through primary care to nephrology specialists for comprehensive evaluation.

Treatment

Treatment for IgA nephropathy focuses on slowing disease progression and managing complications. First-line therapy includes angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to reduce proteinuria and blood pressure. These medications have proven kidney-protective effects.

Recent therapeutic advances include sparsentan, a dual endothelin and angiotensin receptor antagonist approved specifically for IgA nephropathy, and budesonide targeted-release formulation, which delivers corticosteroid therapy directly to the gut-associated lymphoid tissue where IgA is produced.

Supportive care includes blood pressure management with target <130/80 mmHg, dietary protein restriction (0.8-1.0 g/kg/day), sodium restriction, statin therapy for cardiovascular protection, and treatment of complications like anemia and bone disease. In severe cases, traditional immunosuppressive therapy with corticosteroids or other agents may be considered, though this remains controversial due to side effect risks.

Prognosis

The prognosis for IgA nephropathy varies widely among patients. With early diagnosis and appropriate treatment, many patients maintain good kidney function for decades. However, the disease typically follows a slowly progressive course, with approximately 20-40% of patients developing end-stage renal disease within 20 years.

Favorable prognostic factors include younger age at diagnosis, minimal proteinuria (<1 gram/day), normal kidney function at presentation, and absence of high blood pressure. Poor prognostic indicators include heavy proteinuria (>3 grams/day), reduced kidney function at diagnosis, persistent high blood pressure, and certain pathologic features on kidney biopsy.

Recent advances in treatment, particularly with targeted therapies, offer hope for improved long-term outcomes and slower disease progression.

Quality of life

Living with IgA nephropathy requires ongoing attention to kidney health while maintaining an active, fulfilling life. Dietary modifications typically include reducing sodium intake to help control blood pressure, moderating protein intake to reduce kidney workload, and maintaining adequate but not excessive fluid intake.

Exercise and activity are generally encouraged, with regular moderate exercise helping to control blood pressure and maintain cardiovascular health. However, patients should avoid dehydration and excessive physical stress that might temporarily worsen kidney function.

Mental health support is crucial, as living with a chronic kidney condition can cause anxiety about disease progression. Many patients benefit from counseling, support groups, and stress management techniques. Regular monitoring provides reassurance and helps maintain hope through evidence of stable or improving kidney function.

Pregnancy and fertility

IgA nephropathy can affect pregnancy outcomes, particularly in women with significant proteinuria or reduced kidney function. Preconception counseling is essential to optimize blood pressure control and kidney function before pregnancy. Women with well-controlled disease and normal kidney function generally have good pregnancy outcomes.

Medication management during pregnancy requires careful consideration, as ACE inhibitors and ARBs must be discontinued due to fetal risks. Alternative blood pressure medications safe in pregnancy are used instead. Close monitoring by both nephrology and maternal-fetal medicine specialists is recommended throughout pregnancy.

Genetic counseling may be valuable for couples where one partner has IgA nephropathy, though the inheritance pattern is complex and specific genetic testing is not routinely available.

Children

IgA nephropathy can occur in children, though it’s less common than in adults. Pediatric presentation is often similar to adults, with episodes of visible blood in urine following respiratory infections. Children may have a better overall prognosis, particularly those with minimal symptoms at presentation.

Management in children focuses on the same principles as adults but requires careful attention to growth and development. Blood pressure control is crucial, and dietary modifications must ensure adequate nutrition for growing children. Long-term monitoring is essential as the disease may progress slowly over decades.

When to see a doctor

Seek immediate medical attention for visible blood in urine, especially if accompanied by swelling, decreased urination, or severe high blood pressure. Any episode of cola-colored or tea-colored urine following a respiratory infection warrants prompt evaluation.

Routine medical care should be sought for persistent fatigue, gradual swelling in legs or face, or family history of kidney disease. Regular follow-up with a nephrologist is essential for all diagnosed patients, typically every 3-6 months depending on disease severity and stability.

Regional context

While IgA nephropathy occurs worldwide, prevalence varies by geographic region and ethnicity. The condition is most common in Asian populations, particularly in Japan, Korea, and Singapore. In the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean, specific prevalence data is limited, though the condition is recognized by regional nephrologists.

The Global Medical Journal welcomes contributions from healthcare providers in these regions to better understand the local prevalence and management approaches for IgA nephropathy.

Research and clinical trials

Current research focuses on understanding the complex immunologic mechanisms underlying IgA nephropathy and developing targeted therapies. Promising areas include complement pathway inhibitors, B-cell targeted therapies, and agents that modify IgA production and structure.

Recent breakthroughs include the approval of sparsentan and targeted-release budesonide, representing the first specific treatments for IgA nephropathy. Pipeline therapies under investigation include complement inhibitors, APRIL/BAFF pathway inhibitors, and novel anti-inflammatory agents.

Patients interested in clinical trials can search for opportunities at ClinicalTrials.gov using the search term “IgA nephropathy” to find current studies recruiting participants.

Frequently asked questions

Is IgA nephropathy hereditary?

IgA nephropathy has a multifactorial inheritance pattern involving multiple genetic and environmental factors. While family clustering occurs in 5-10% of cases, most cases are sporadic with no clear family history.

Will I need dialysis or a kidney transplant?

Not all patients with IgA nephropathy will require dialysis or transplantation. With early diagnosis and appropriate treatment, many patients maintain adequate kidney function for decades. About 20-40% may eventually need renal replacement therapy.

Can IgA nephropathy come back after kidney transplant?

IgA nephropathy can recur in transplanted kidneys, occurring in about 20-30% of patients. However, recurrence is often mild and rarely leads to transplant loss, especially with modern immunosuppressive protocols.

Should I avoid certain foods or medications?

Dietary modifications typically include reducing sodium and moderating protein intake. Avoid nephrotoxic medications like NSAIDs (ibuprofen, naproxen) when possible. Some patients benefit from avoiding gluten, though evidence is limited.

How often do I need monitoring?

Monitoring frequency depends on disease severity and stability. Most patients need evaluation every 3-6 months with urine tests, blood work to check kidney function, and blood pressure measurement. More frequent monitoring may be needed during active phases or treatment changes.

Support and resources

IgA Nephropathy Foundation – www.igan.org – Primary patient advocacy organization providing education, support, and research funding.

National Organization for Rare Disorders (NORD) – rarediseases.org

Orphanet – orpha.net – European reference portal for rare diseases and orphan drugs.

National Kidney Foundation – kidney.org – Comprehensive kidney disease resources and support.

American Kidney Fund – kidneyfund.org – Financial assistance and educational resources.

Related conditions

Lupus nephritis
Minimal change disease
Membranous nephropathy
Focal segmental glomerulosclerosis
Chronic kidney disease

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.